Philip E. Silkoff

Philip E. Silkoff

Auto-generated profile, based on publicly available information

Philip E. Silkoff

Janssen Research & Development LLC, Spring House, Pa

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1997 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
PSP E Silkoff
P E Silkoff
PMP A McClean
P A McClean
ASA S Slutsky
A S Slutsky
HFH G Furlott
H G Furlott
EHE Hoffstein
E Hoffstein
NZN Zamel
N Zamel
Exhaled nitric oxide (NO) may aid in monitoring pulmonary disease. The single-breath NO profile (subjects with nose clip) was described as a NO peak followed by a plateau (NO(PLAT)). Published exhaled NO values vary greatly, possibly due to contamination with nasal NO and differing respiratory maneuvers. We developed a technique to measure pulmonary NO, without nasal NO, by having the subject maintain a positive expiratory pressure (ensuring vellum closure), and we examined the variation in NO(PLAT) over a range of expiratory flows (4.2 to 1,550 ml/s). NO(PLAT) values rose almost 35-fold (3.2 +/- 1.4 ppb to 110.5 +/- 54.8 ppb) with decreasing flow, described by NO(PLAT) = 208.6795 x (flow rate)(-0.5995). However, NO excretion showed an almost 11-fold rise as flow increased. In summary, we present a simple technique for measuring exhaled NO without contamination by nasal NO. There is a marked flow dependence of exhaled NO concentration and excretion. Exhaled pulmonary NO is best measured at very low flow rates to amplify the signal and must be related to the expiratory flow employed.

1 September 2010 in Chest
Verified
Journal Article
Closed access
PBPeter Barnes
Peter Barnes
RDRaed A. Dweik
Raed A. Dweik
AGArthur F. Gelb
Arthur F. Gelb
PGpeter gibson
peter gibson
SGSteven C. George
Steven C. George
NZNoe Zamel
Noe Zamel

1 June 2005 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
FBFrederik Buchvald
Frederik Buchvald
EBEugenio Baraldi
Eugenio Baraldi
SCSilvia Carraro
Silvia Carraro
BGBenjamin Gaston
Benjamin Gaston
JJJohan De Jongste
Johan De Jongste
HBHans Bisgaard
Hans Bisgaard

1 July 2002 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MFMembers Of The Task Force
Members Of The Task Force
EBEugenio Baraldi
Eugenio Baraldi
JJJ.C. de Jongste
J.C. de Jongste
BGB. Gaston
B. Gaston
KAKjell Alving
Kjell Alving
SSS. Stick
S. Stick
Measurement of fractional exhaled nitric oxide in exhaled air is an exciting innovative technique that gives new insights in to the pathophysiology of lung disease and asthma in particular, with many potential clinical applications. Careful standardisation of measurement techniques will facilitate the use of this new measurement in paediatric respiratory medicine; this Task Force was set up for this purpose. Methodologies, for use in all age groups, are already available and there are abundant questions relating to interpretation and application of fractional exhaled nitric oxide waiting to be addressed. Noninvasiveness and instantaneous results potentially make it a suitable monitoring instrument for use in children. Exhaled nitric oxide measurement has definitely found its way into clinical research in paediatric respiratory medicine. Evidence for clinically-useful applications is accumulating, and the merits of this new technique must now be demonstrated in larger studies, using standardised methodology in an appropriate setting.

1 April 2000 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
PSPhilip E. Silkoff
Philip E. Silkoff
JSJimmie T. Sylvester
Jimmie T. Sylvester
NZNoe Zamel
Noe Zamel
SPSolbert Permutt
Solbert Permutt
If the nitric oxide (NO) diffusing capacity of the airways (Dno) is the quantity of NO diffusing per unit time into exhaled gas (q̇) divided by the difference between the concentration of NO in the airway wall (C w) and lumen, then Dno and Cw can be estimated from the relationship between exhaled NO concentration and expiratory flow. In 10 normal subjects and 25 asthmatic patients before and after treatment with inhaled beclomethasone, Dno averaged 6.8 ± 1.2, 25.5 ± 3.8, and 22.3 ± 2.7 nl/s/ppb × 10− 3, respectively; Cw averaged 149 ± 31.9, 255.3 ± 46.4, and 108.3 ± 14.3 ppb, respectively; and DnoCw (the maximal q̇ from diffusion) averaged 1,020 ± 157.5, 6,512 ± 866, and 2,416 ± 208.5 nl/s × 10− 3, respectively. Dno and DnoCw in the asthmatic subjects before and after steroids were greater than in normal subjects (p < 0.0001), but Cw was not different. Within asthmatic subjects, steroids caused Cw and DnoCw to fall (p < 0.0001), but Dno was unchanged. DnoCw after steroids, presumably reflecting maximal diffusion of constitutive NO, was positively correlated with methacholine PC20 and FEV1/FVC before or after steroids. The increased Dno measured in asthmatic patients may reflect upregulation of nonadrenergic, noncholinergic, NO-producing nerves in airways in compensation for decreased sensitivity of airway smooth muscle to the relaxant effects of endogenous NO.

1 January 2008 in Drugs
Verified
Journal Article
Closed access
PDF file
DTDonald P. Tashkin
Donald P. Tashkin
SRStephen I Rennard
Stephen I Rennard
PMPaula Martin
Paula Martin
SRSulabha Ramachandran
Sulabha Ramachandran
UMUbaldo J. Martin
Ubaldo J. Martin
MGMitchell Goldman
Mitchell Goldman